Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Blood Coagul Fibrinolysis ; 19(6): 483-7, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18685430

RESUMO

Chondroitin-4-sulfate was oversulfated using chlorosulfonic acid-pyridine complex and was isolated as the sodium salt. A comparison of the infrared analysis of the native (N-2) and oversulfated (S-2) compounds showed that the two spectra were identical except for a new peak in S-2 at 825 cm corresponding to the equatorial C-6 position of galactosamine. There was a 2.7-fold increase of sulfate content in S-2 and a generation of a significant anticoagulant activity as measured by doubling of the prothrombin time of normal citrated human plasma using 7.5 microg, while N-2 was inactive even at 2,000 microg. The result of the in-vitro studies of the activation of glutamic plasminogen by tissue plasminogen activator (t-PA) or by high-molecular-weight urokinase using 0.05 mol/l Tris buffer (pH 7.35) containing a physiological concentration of NaCl (0.9%) showed that 28.6 microg/ml S-2 enhanced the activation by three-fold to four-fold by t-PA or by urokinase, while the same concentrations of N-2 or unfractionated heparin gave less than 30% enhancement of t-PA and no enhancement of urokinase. The mechanism of enhancement by S-2 was investigated by dilution studies. The results showed that S-2 interacted with both urokinase or t-PA and glutamic plasminogen favoring a template model, while N-2 or unfractionated heparin interacted only with t-PA.


Assuntos
Sulfatos de Condroitina/química , Sulfatos/análise , Coagulação Sanguínea/efeitos dos fármacos , Interações Medicamentosas , Ativação Enzimática/efeitos dos fármacos , Fibrinolisina/biossíntese , Heparina/farmacologia , Humanos , Plasma , Plasminogênio/efeitos dos fármacos , Plasminogênio/metabolismo , Tempo de Protrombina , Piridinas/farmacologia , Espectrofotometria Infravermelho , Ácidos Sulfônicos/farmacologia , Tromboplastina/farmacologia , Ativador de Plasminogênio Tecidual/farmacologia , Ativador de Plasminogênio Tipo Uroquinase/farmacologia
2.
Blood Coagul Fibrinolysis ; 19(1): 60-5, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18180617

RESUMO

Fucoidan and chondroitin-6-sulfate were oversulfated using chlorosulfonic acid-pyridine complex and were isolated as the sodium salt. Infrared analysis of oversulfated compounds showed introduction of sulfate groups in new positions, and in-vitro studies of the compounds showed a significant increase in the anticoagulant property. Addition of 28.6 microg/ml oversulfated compound gave a two-fold to four-fold increase in the rate of enhancement of activation of glutamic plasminogen by tissue plasminogen activator using 0.05 mol/l Tris buffer (pH 7.35) containing physiological concentrations of NaCl (0.9%). Under these conditions, unfractionated heparin was not active and the native compounds gave less than 30% enhancement. In the present study, the effect of lysine or cyanogen bromide-treated fibrinogen, alone or in combination with the oversulfated compounds, on the activation of glutamic plasminogen by tissue plasminogen activator was investigated. Addition of 16.2 mmol/l L-lysine gave three-fold to four-fold enhancement of activation, which was further enhanced to five-fold to six-fold by addition of 2.86 microg/ml oversulfated chondroitin-6-sulfate or oversulfated fucoidan. Cyanogen bromide-treated fibrinogen (50 microg/ml) gave a 10-fold enhancement of activation by itself, and addition of 2.86 microg/ml oversulfated compounds amplified this to 15-fold. A 25-fold to 35-fold enhancement of activation of glutamic plasminogen was obtained when 2.86 microg/ml oversulfated compounds were combined with 16.2 mmol/l lysine and 50 microg/ml cyanogen bromide-treated fibrinogen. Dilution studies showed that the amplification of the enhancement of lysine by 2.86 microg/ml oversulfated compound was related to interaction of the cofactors with both glutamic plasminogen and tissue plasminogen activator.


Assuntos
Sulfatos de Condroitina/farmacologia , Lisina/farmacologia , Plasminogênio/efeitos dos fármacos , Polissacarídeos/farmacologia , Sulfatos de Condroitina/química , Brometo de Cianogênio/química , Brometo de Cianogênio/farmacologia , Interações Medicamentosas , Fibrinogênio/química , Fibrinogênio/fisiologia , Humanos , Plasminogênio/fisiologia , Polissacarídeos/química , Ligação Proteica , Relação Estrutura-Atividade , Sulfatos/química , Ativador de Plasminogênio Tecidual/efeitos dos fármacos , Ativador de Plasminogênio Tecidual/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...